

Contact Information

Please consult the Summary of Product Characteristics for Lunsumio (mosunetuzumab) available at: www.medicines.org.uk if based in Great Britain or www.emcmedicines.com/en-gb/northernireland if based in Northern Ireland; or contact Roche Medical Information (tel: 0800 328 1629, email: medinfo.uk@roche.com).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the Patient Information Leaflet. You can also report side effects directly via the national reporting system:

Yellow Card Scheme at Website: www.mhra.gov.uk/yellowcard, MHRA Yellow Card in the Google Play or Apple App Store.

You should also report side effects to Roche Products Ltd by emailing the Roche Drug Safety Centre at welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. By reporting side effects you can help provide more information on the safety of this medicine.

Date of Lunsumio (mosunetuzumab) initiation:

Name of haematologist:

Contact Number:

After-hours contact number:

My name:

My contact number:

Emergency contact:

Emergency contact number:

Roche

Important Safety Information for Patients receiving Lunsumio® (mosunetuzumab) ▼

Lunsumio is used to treat patients with follicular lymphoma

Patient Card

This educational material is provided by Roche Products Limited. This card provides information about cytokine release syndrome.

M-GB-00008031 Date of preparation: October 2022
Version 1.1 MHRA Approval Date: November 2022

Please carry this card with you at all times while you are receiving Lunsumio (mosunetuzumab).

Show this card to ALL Healthcare Professionals (including doctors, nurses, pharmacists) involved in your treatment and at any visits to the hospital.

Important Information for the Patient

Contact your Doctor or get emergency help right away if you have any of these symptoms. Do not attempt to diagnose and treat these symptoms yourself.

- Fever (100.4°F/38°C or higher)
- Fast or irregular heartbeat
- Chills or shaking chills
- Confusion
- Severe fatigue or weakness
- Difficulty breathing
- Dizziness or light-headedness
- Fainting or blurred vision
- Cold or pale clammy skin
- Headache

Experiencing any of these symptoms could be due to **Cytokine Release Syndrome**, which requires immediate evaluation by a Doctor.

Cytokine Release Syndrome (CRS)

- is a group of symptoms caused by small proteins called cytokines, released in your body during inflammation.
- CRS may involve any organ systems and can be serious and life-threatening.
- may be caused by receiving Lunsumio (mosunetuzumab).

Please refer to the Patient Information Leaflet (PIL) for Lunsumio (mosunetuzumab) for more information, which is available at: www.medicines.org.uk if based in Great Britain or www.emcmedicines.com/en-gb/northernireland if based in Northern Ireland.

Important Information for Healthcare Professionals

This patient has received *Lunsumio*®▼ (*mosunetuzumab*) - **which may cause Cytokine Release Syndrome (CRS).**

- Evaluate the patient immediately for signs and symptoms of CRS and treat symptoms accordingly.
- CRS may involve any organ systems and can be serious and life-threatening.
- If CRS is suspected, please refer to the latest product information for Lunsumio (mosunetuzumab) for comprehensive instructions on CRS management.
- **Contact the prescribing doctor immediately for further information** – they may need to modify the next infusion of Lunsumio (mosunetuzumab).